A Long Term Extension Study to Evaluate the Safety and Efficacy of Afimkibart (RO7790121) in Participants With Atopic Dermatitis
Recruiting now · Phase 2
Conditions studied: Atopic Dermatitis
In brief
This study will assess long-term safety and efficacy of Afimkibart (also known as RO7790121) in participants with Atopic Dermatitis (AD) who participated in previous afimkibart clinical trials.
Key facts
- Study ID
- NCT07223697
- Run by
- Hoffmann-La Roche
- People needed
- 120
- Starts
- 2026-01-08
- Expected to finish
- 2033-03-01
- Last updated by the study team
- 2026-08-06
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Ability and willingness to comply with all aspects of the protocol including completion of the efficacy assessments (EASI and IGA), clinical outcome assessment instruments (DLQI, POEM), and safety and PK sample collections for the duration of the study
- Parent Clinical Trial-Specific Criteria:
- Study CS45570 participants who continued to be evaluated at the Week 36 follow up visit and achieved => EASI50 response from study baseline
You may not qualify if…
- Evidence of other skin conditions that would interfere with the assessment of AD
- Withdrawal of consent and/or premature discontinuation from parent study
- Any permanent discontinuation of study drug in parent study
- History of severe allergic reaction or anaphylactic reaction to any biologic agent or known hypersensitivity to any component of Afimkibart
Where it is running
- UCLA Division of Dermatology — Los Angeles, California, United States (enrolling)
- Olympian Clinical Research — Tampa, Florida, United States (enrolling)
- Hamilton Research, LLC — Alpharetta, Georgia, United States (enrolling)
- Revival Research Institute, LLC — Troy, Michigan, United States (enrolling)
- Best Skin Research LLC — Camp Hill, Pennsylvania, United States (enrolling)
- Centro de Estudos em Terapias Inovadoras ? CETI — Curitiba, Paraná, Brazil (enrolling)
- Irmandade Da Santa Casa de Misericordia de Porto Alegre — Porto Alegre, Rio Grande do Sul, Brazil (enrolling)
- Hospital de Clnicas de Porto Alegre — Porto Alegre, Rio Grande do Sul, Brazil (enrolling)
- UNESP - Faculdade de Medicina da Universidade Estadual Paulista - Campus Botucatu — Botucatu, São Paulo, Brazil (enrolling)
- Centro de Pesquisa São Lucas — Campinas, São Paulo, Brazil (enrolling)
- HMCG - Hospital e Maternidade Dr. Christovo da Gama — Santo Andr, São Paulo, Brazil (enrolling)
- Fundacao Faculdade Regional de Medicina de Sao Jose Do Rio Preto Hospital de Base - PPDS — Sao Jose Rio Preto, São Paulo, Brazil (enrolling)
- Instituto Brasil de Pesquisa Clínica-IBPCLIN S/A — Rio de Janeiro, Brazil (enrolling)
- DermEffects — London, Ontario, Canada (enrolling)
- Lynderm Research Inc — Markham, Ontario, Canada (enrolling)
- DermEdge — Mississauga, Ontario, Canada (enrolling)
- Ryan Clinical Research Inc — Newmarket, Ontario, Canada (enrolling)
- Fachklinik Bad Bentheim — Bad Bentheim, Lower Saxony, Germany (enrolling)
- Dermatologikum Hamburg Gemeinschaftspraxis GbR — Hamburg, Germany (enrolling)
- Azienda Ospedaliero Universitaria delle Marche — Ancona, The Marches, Italy (enrolling)
- Centrum Medyczne Pratia Katowice I — Katowice, Silesian Voivodeship, Poland (enrolling)
- Centrum Medyczne Pratia Gdynia — Gdynia, Poland (enrolling)
- Specjalistyczny Gabinet Dermatologiczny dr n. med. Pawel Brzewski — Krakow, Poland (enrolling)
- Centrum Nowoczesnych Terapii "Dobry Lekarz" — Krakow, Poland (enrolling)
- Uniwersytecki Szpital Kliniczny im.Fryderyka Chopina w Rzeszowie — Rzeszów, Poland (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.